2017
The vascular endothelial specific IL-4 receptor alpha–ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions
Yamani A, Wu D, Waggoner L, Noah T, Koleske AJ, Finkelman F, Hogan SP. The vascular endothelial specific IL-4 receptor alpha–ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions. Journal Of Allergy And Clinical Immunology 2017, 142: 1159-1172.e5. PMID: 29157947, PMCID: PMC5957775, DOI: 10.1016/j.jaci.2017.08.046.Peer-Reviewed Original ResearchConceptsIgE-mediated anaphylactic reactionsAnaphylactic reactionsFluid extravasationIL-4RαBarrier dysfunctionIL-4Food-induced anaphylactic reactionsIgE-induced anaphylaxisFood-induced anaphylaxisIgE-mediated anaphylaxisIL-4 receptor α chainIgE-mediated reactionsTreatment of miceSevere anaphylactic reactionsSeverity of anaphylaxisABL kinase inhibitor imatinibKinase inhibitor imatinibReceptor α chainVe cell linesVenous vasodilatationOral antigenHypovolemic shockInhibitor imatinibAnaphylaxisVe cells
2010
ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1
Thai M, Ting P, McLaughlin J, Cheng D, Müschen M, Witte O, Colicelli J. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia 2010, 25: 290-300. PMID: 21102429, PMCID: PMC3049868, DOI: 10.1038/leu.2010.268.Peer-Reviewed Original ResearchConceptsBCR-ABL1Imatinib-resistant diseaseFirst-line therapyAcute lymphocytic leukemiaChronic myeloid leukemiaBCR-ABL1 kinase activityABL kinase inhibitor imatinibKinase inhibitor imatinibBCR-ABL1 activityBone marrow cellsAbl kinase inhibitorsDrug-resistant mutantsLeukemic casesMyeloid leukemiaLymphocytic leukemiaCell-autonomous mechanismsETV6-ABL1Inhibitor imatinibTyrosine kinase fusion proteinActive tyrosine kinaseMarrow cellsHematopoietic malignanciesKinase inhibitorsKinase fusion proteinGene translocation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply